Stoke Therapeutics (STOK) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Stoke Therapeutics (STOK) over the past year, gaining 113.4% versus a loss of 21.5%. Over five years, URGN leads with a +117.3% price change compared with +1.8% for STOK. UroGen Pharma is the larger company by market cap ($1.81 billion vs $1.55 billion), about 1.2 times the size, while Stoke Therapeutics is growing revenue faster (+404.5% vs +21.4%).
Stoke Therapeutics converts more of its revenue into profit, with a net margin of -3.7% versus -139.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | STOK | URGN |
|---|---|---|
| Share price | $23.95 | $36.98 |
| Market cap | $1.55B | $1.81B |
| 1-day change | -1.40% | -9.14% |
| YTD return | -24.54% | +57.90% |
| 1-year return | -21.48% | +113.39% |
| 5-year return | +1.83% | +117.27% |
| Forward P/E | — | 13.23 |
| EPS (TTM) | $-3.38 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $184.42M | $109.79M |
| Revenue growth (YoY) | +404.50% | +21.45% |
| Net income (latest FY) | $-6.88M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | -11.16% | -113.73% |
| Net margin | -3.73% | -139.81% |
| 52-week high | $40.22 | $50.81 |
| 52-week low | $20.32 | $15.86 |
| Distance from 52-week high | -40.45% | -27.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +93.99% | +62.25% |
| Average volume | 855.13K | 849.01K |
| Shares outstanding | 64.53M | 48.88M |
| Employees | 170 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed STOK by 134.9 percentage points over the past year.
- Stoke Therapeutics is more profitable, keeping -3.7 cents of every revenue dollar as net income versus -139.8 cents for UroGen Pharma.
- Stoke Therapeutics grew revenue faster in its latest fiscal year (+404.50% vs +21.45%).
About Stoke Therapeutics
STOK stock →Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Health Care · Biotechnology: Pharmaceutical Preparations · 170 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
STOK vs URGN FAQ
Which is bigger, Stoke Therapeutics or UroGen Pharma?
UroGen Pharma (URGN) is larger, with a market capitalization of $1.81B compared with $1.55B for Stoke Therapeutics (STOK).
Which stock has performed better over the past year, STOK or URGN?
URGN returned +113.39% over the past 12 months, compared with -21.48% for STOK (price return, excluding dividends). Past performance does not predict future results.
Are Stoke Therapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.